Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This expansion increases access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
The Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while the PrecisionCHD test helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks. The coverage through Atlas Healthcare Physicians will allow more patients in managed care plans to benefit from these advanced diagnostic tools without the need for invasive procedures.
This move is significant as cardiovascular disease remains the leading cause of death globally, and early detection and risk assessment are critical for effective prevention and management. By integrating AI-driven genetic and epigenetic analysis, Cardio Diagnostics aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s core technology leverages an Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine to develop and commercialize clinical tests for cardiovascular disease.
The expansion into Atlas Healthcare Physicians’ network could have a substantial impact on patient outcomes in Southern California, where managed care populations often face barriers to accessing advanced diagnostic technologies. With prior authorization, eligible members can now receive these tests, which may lead to earlier intervention and more tailored treatment plans. This aligns with the broader trend toward precision medicine, where treatments are customized based on individual genetic and epigenetic profiles.
For the healthcare industry, this announcement underscores the growing role of AI in cardiovascular diagnostics and the potential for noninvasive tests to replace more traditional, invasive methods. It also highlights the importance of partnerships between diagnostic companies and physician associations to broaden patient access. As more payers and provider networks adopt such technologies, the standard of care for coronary heart disease could shift toward more precise and personalized approaches.
Cardio Diagnostics continues to advance its mission of improving cardiovascular disease prevention, detection, and treatment. The company’s newsroom provides the latest updates on its progress. For more information about the press release, visit the full release. As with any forward-looking statements, the company cautions that actual results may differ materially due to risks and uncertainties, as detailed in its filings with the SEC.
